OS Therapies a clinical-stage biotechnology company focused on developing immunotherapies and targeted drug conjugates to treat cancer, has provided a comprehensive update to the market regarding its recent achievements and plans for the future. This announcement comes on the heels…
OA Pain Zoetis Updates U.S. Label for Librela® to Enhance Support for Veterinarians and Pet Owners OA Pain Zoetis a global leader in animal health, has announced a key update to the U.S. label for Librela® (bedinvetmab injection). This change…
Tonix Pharmaceuticals Appoints Siobhan Fogarty as Chief Technical Officer Tonix Pharmaceuticals Holding a fully integrated biopharmaceutical company specializing in the development and commercialization of innovative therapies for pain management and other health challenges, has announced the promotion of Siobhan Fogarty…
Marquis Who’s Who Recognizes Dr. Daniel L. Shungu for Leadership in Disease Control Daniel L. Shungu, PhD, has been honored with inclusion in Marquis Who’s Who, a prestigious recognition awarded to individuals with remarkable achievements, leadership, and contributions in their…
Enveric Biosciences Completes $5 Million Public Offering Enveric Biosciences a leading biotechnology company focused on the development of groundbreaking neuroplastogenic small-molecule therapeutics, has made a significant advancement in its efforts to address some of the most pressing challenges in mental…
Bayer has officially submitted a marketing authorization application to the European Medicines Agency (EMA), seeking approval for the use of finerenone in adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40% or greater. This…
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that it has secured a reimbursement agreement with NHS England, providing eligible sickle cell disease (SCD) patients access to its groundbreaking CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement represents a significant advancement in…
Galderma’s Breakthrough Findings Galderma (SWX:GALD), a global leader in dermatology, has announced the results of its Phase IIIb RELAX clinical trial, demonstrating the rapid onset, long-lasting efficacy, and high patient satisfaction of RelabotulinumtoxinA (Relfydess™) for treating frown lines (glabellar lines).…
The “Biological Drugs – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offerings, providing an in-depth analysis of the market’s current landscape, trends, and future projections. The global biological drugs market was valued at approximately USD 345.3 billion in…
The global Pharmaceutical R&D Outsourcing market is set to grow significantly, with a valuation of USD 84.01 billion in 2023 and expected to reach USD 150.04 billion by 2029, representing a compound annual growth rate (CAGR) of 10.15%. This growth…
PFID Poll: Bipartisan Support for Continued Vaccine Availability and Concern Over Declining Childhood Vaccination Rates The Partnership to Fight Infectious Disease (PFID) has released the results of a public opinion poll that highlights a strong consensus among American voters on…
ImmunityBio, Inc. (NASDAQ: IBRX) has announced a strategic collaboration and supply agreement with BeiGene, Ltd. (soon to be renamed BeOne Medicines, Ltd.), a global oncology company. The partnership will focus on conducting a confirmatory, randomized Phase 3 clinical trial (ResQ201A-NSCLC),…